From animal models to patients: new therapies for Charcot-Marie-Tooth disease (CMT)

Research report (imported) 2018 - Max Planck Institute for Multidisciplinary Sciences

Authors
Sereda, Michael W.; Fledrich, Robert; Prukop, Thomas; Stassart, Ruth; Nave, Klaus-Armin
Departments
Abteilung "Molecular and Translational Neurology"
DOI
Summary
Charcot-Marie-Tooth disease (CMT) is the most common hereditary neuropathy of the peripheral nervous system. So far no treatment is available. Using transgenic animal models, we have developed new therapeutic approaches which are currently being translated to humans, thus creating new therapeutic options for approximately 1.5 million affected CMT patients worldwide.

For the full text, see the German version.

Zur Redakteursansicht